Literature DB >> 9580814

Post-kala-azar dermal leishmaniasis with mucosal involvement in a kidney transplant recipient: treatment with liposomal amphotericin B.

G Roustan1, J A Jiménez, B Gutiérrez-Solar, J L Gallego, J Alvar, M Patrón.   

Abstract

Post-kala-azar dermal leishmaniasis (PKDL) is a rare clinical variant of cutaneous leishmaniasis. It is very common in the Indian subcontinent and less frequent in East Africa, but exceptional in the American and European continents. We have observed a case of PKDL in a renal transplant recipient. No systemic symptoms were present. The patient was treated with liposomal amphotericin B. We emphasize the unusual aspects of this case: the appearance of PKDL in Europe, its relationship with immunosuppression, the severe mucosal involvement and the excellent response to liposomal amphotericin B, a newly described treatment for the disease.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9580814     DOI: 10.1046/j.1365-2133.1998.02139.x

Source DB:  PubMed          Journal:  Br J Dermatol        ISSN: 0007-0963            Impact factor:   9.302


  8 in total

1.  Transplantation in the tropics: lessons on prevention and management of tropical infectious diseases.

Authors:  Ligia C Pierrotti; Camille N Kotton
Journal:  Curr Infect Dis Rep       Date:  2015-07       Impact factor: 3.725

Review 2.  The relationship between leishmaniasis and AIDS: the second 10 years.

Authors:  Jorge Alvar; Pilar Aparicio; Abraham Aseffa; Margriet Den Boer; Carmen Cañavate; Jean-Pierre Dedet; Luigi Gradoni; Rachel Ter Horst; Rogelio López-Vélez; Javier Moreno
Journal:  Clin Microbiol Rev       Date:  2008-04       Impact factor: 26.132

Review 3.  Solid Organ Transplant and Parasitic Diseases: A Review of the Clinical Cases in the Last Two Decades.

Authors:  Silvia Fabiani; Simona Fortunato; Fabrizio Bruschi
Journal:  Pathogens       Date:  2018-07-31

4.  Visceral Leishmaniasis IgG1 Rapid Monitoring of Cure vs. Relapse, and Potential for Diagnosis of Post Kala-Azar Dermal Leishmaniasis.

Authors:  Tegwen Marlais; Tapan Bhattacharyya; Om Prakash Singh; Pascal Mertens; Quentin Gilleman; Caroline Thunissen; Bruno C Bremer Hinckel; Callum Pearson; Bathsheba L Gardner; Stephanie Airs; Marianne de la Roche; Kiera Hayes; Hannah Hafezi; Andrew K Falconar; Osama Eisa; Alfarazdeg Saad; Basudha Khanal; Narayan Raj Bhattarai; Suman Rijal; Marleen Boelaert; Sayda El-Safi; Shyam Sundar; Michael A Miles
Journal:  Front Cell Infect Microbiol       Date:  2018-12-13       Impact factor: 5.293

5.  Histopathology of Post Kala-azar Dermal Leishmaniasis.

Authors:  V Ramesh; M Ramam
Journal:  Indian J Dermatol       Date:  2020 Nov-Dec       Impact factor: 1.494

6.  Therapeutic Modalities in Post Kala-azar Dermal Leishmaniasis: A Systematic Review of the Effectiveness and Safety of the Treatment Options.

Authors:  Adrija Datta; Indrashis Podder; Anupam Das; Amrita Sil; Nilay Kanti Das
Journal:  Indian J Dermatol       Date:  2021 Jan-Feb       Impact factor: 1.494

7.  Post-kala-azar dermal leishmaniasis with mucosal involvement: an unusual case presentation including successful treatment with miltefosine.

Authors:  Md A Salam; Muhammad A Siddiqui; Shah G Nabi; Khondaker R H Bhaskar; Dinesh Mondal
Journal:  J Health Popul Nutr       Date:  2013-06       Impact factor: 2.000

8.  Atypical Presentation of PKDL due to Leishmania infantum in an HIV-Infected Patient with Relapsing Visceral Leishmaniasis.

Authors:  Benedetto Maurizio Celesia; Bruno Cacopardo; Daniela Massimino; Maria Gussio; Salvatore Tosto; Giuseppe Nunnari; Marilia Rita Pinzone
Journal:  Case Rep Infect Dis       Date:  2014-08-14
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.